The rare skin cancer Merkel cell carcinoma (MCC) has demonstrated profound responsiveness to PD-1/PD-L1 blockade, with some of the highest response rates (56%–62%) obtained among all solid cancers (2–4). Here, PDCD1 is linked to Merkel cell skin cancer.